A new test to predict melanoma recurrence using DNA analysis
Official title: Analytical and Clinical Validation of an EPIC 900K v2 array-based methylation assay to predict recurrence in stage II melanoma
Funded at New York University School of Medicine · NIH-11039026 · Data updated 2026-11-12
This study is looking to create a new test that checks DNA markers in patients with stage II melanoma to better predict if their cancer might come back, helping doctors decide who might need extra treatment and who can avoid unnecessary ones.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 3, 2025 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $310,185 |
| NIH project number | 1UH2CA290587-01A1 |
| Project ID | NIH-11039026 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with stage II melanoma who have undergone surgical resection.
✕Less likely to help
Patients with stage I or stage III melanoma, or those who have not had surgery, may not benefit from this research.
What this research studies
This research aims to develop and validate a DNA methylation assay that can predict the likelihood of recurrence in patients with stage II melanoma. By analyzing specific DNA markers, the study seeks to improve the accuracy of prognostic assessments beyond traditional histopathology. This could help identify patients who are at a higher risk of recurrence and may benefit from additional treatments, while also sparing others from unnecessary therapies. The approach involves using advanced genomic technologies to analyze tumor samples from patients.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for melanoma patients, improving outcomes and reducing unnecessary treatment side effects.
How similar studies have gone: Previous research has shown promising results in using DNA methylation markers for cancer prognosis, suggesting that this approach could be effective for melanoma as well.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Polsky, David — New York University School of Medicine
- Study coordinator: Polsky, David
Related research
Other NIH-funded projects on the same topics.
-
AI to predict melanoma coming back using tumor images, gene data, and pathology
This project is building an AI tool that uses detailed tumor pictures, gene activity, and pathology reports to help doctors predict whether early-stage (stage I or II) melanoma might return.
-
Dormant melanoma cells and aging: how the tissue environment shapes recurrence
This NIH grant studies how aging tissue environments influence melanoma dormancy and late recurrences, with a focus on how aged lung fibroblasts and Wnt signaling affect cancer cell reawakening.
-
Methylation test to predict melanoma recurrence after surgery
A patient-facing test uses a DNA methylation pattern to help doctors predict if stage II melanoma might come back after surgery.
-
Using advanced AI to predict melanoma recurrence by analyzing imaging and genetic data.
This study is looking to help people with early-stage melanoma by using advanced imaging and genetic information to better predict if their cancer might come back, so they can receive more personalized care and monitoring based on their specific risk.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
-
Combined Imaging and RNA Markers to Predict Head and Neck Cancer Recurrence
A research project aims to use imaging and RNA data to better predict if head and neck cancer will come back, helping doctors tailor treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.